Evidence map›Paper›PMID 41916955›Full record

ArticleBlood cancer journal2026

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad Alrawabdeh, Marah Alzu'bi, Carolina D Schinke, Sharmilan Thanendrarajan, John D Shaughnessy and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Hira Cheema *Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Asis Shrestha *Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Syed NaqviMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Sanjay MuttineniMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Sasya DronavalliMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Jawad AlrawabdehDepartment of Internal Medicine, University of Jordan, Amman, Jordan.
Marah Alzu'biDepartment of Internal Medicine, University of Jordan, Amman, Jordan.
Carolina D SchinkeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0002-2699-1741
Sharmilan ThanendrarajanMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
John D ShaughnessyMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Fenghuang ZhanMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0001-5417-2973
Maurizio ZangariMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Frits van RheeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0001-9959-1282
Samer Al HadidiMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA. Samer.AlHadidi@UTSouthwestern.edu.ORCID http://orcid.org/0000-0003-4297-8042

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teclistamab, a bispecific T-cell engager targeting BCMA and CD3, has demonstrated efficacy in relapsed/refractory multiple myeloma but may increase infection risk due to immunosuppression. Cytomegalovirus (CMV) reactivation is a concern in immunocompromised patients, yet its incidence and clinical significance in teclistamab-treated patients remain poorly characterized. We conducted a retrospective analysis of 177 multiple myeloma patients who received teclistamab between December 2022 and December 2024. We assessed CMV reactivation incidence, risk factors, and clinical outcomes. Binary logistic regression identified predictors of CMV reactivation. CMV testing was done in 173 (98%) patients. CMV reactivation occurred in 38 patients (22%) during teclistamab treatment, with a median initial viral load of 87.2 IU/mL (range: 37.1-4807.0). The median highest CMV level was 288 IU/mL (range: 45.3-20,000). Most reactivations were asymptomatic (89.5%), with only four symptomatic cases, three requiring treatment, and no end-organ damage. Eight patients (21.1%) experienced second viremia episodes. Multivariable analysis identified prior CMV reactivation as a significant predictor (OR = 3.34, p = 0.005). CMV reactivation did not impact overall survival (p = 0.673). Prophylactic IVIG use was associated with improved survival (HR = 0.49, p = 0.011). CMV reactivation occurs in approximately one-fifth of teclistamab-treated multiple myeloma patients but is typically asymptomatic and does not affect survival. Prior CMV reactivation predicts subsequent reactivation. These findings support risk-stratified CMV monitoring approaches in this population.

Indexed as

CytomegalovirusCytomegalovirus InfectionsMultiple MyelomaVirus ActivationAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment Outcome

Identifiers

PMID41916955
PMCPMC13039453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.